
## Ayumi Sugiura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/204398/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. Medicina (Lithuania), 2021, 57, 280.	2.0	3
2	Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. PLoS ONE, 2021, 16, e0249435.	2.5	1
3	Quantitative and qualitative lipid improvement with chronic hepatitisÂC virus eradication using directâ€acting antivirals. Hepatology Research, 2021, 51, 758-766.	3.4	3
4	Investigation of the Effect of KIR–HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. Cancers, 2021, 13, 3267.	3.7	6
5	Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. Journal of Infection and Chemotherapy, 2021, 27, 1750-1755.	1.7	3
6	aMAP score prediction of hepatocellular carcinoma occurrence and incidenceâ€free rate after a sustained virologic response in chronic hepatitis C. Hepatology Research, 2021, 51, 933-942.	3.4	15
7	Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project. PLoS ONE, 2021, 16, e0256711.	2.5	2
8	Clinical utility of FibroScan as a nonâ€invasive diagnostic test for primary biliary cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1208-1214.	2.8	17
9	Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. Biomedicines, 2020, 8, 74.	3.2	11
10	Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatology Research, 2019, 49, 1236-1243.	3.4	24
11	Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving directâ€acting antivirals. Journal of Viral Hepatitis. 2018. 25. 1462-1471.	2.0	21